Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels

Summary

The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) to K/DOQI recommended targets in subjects with end stage renal disease (ESRD) receiving hemodialysis, on bio-intact parathyroid hormone, corrected serum calcium, serum phosphorus, and calcium phosphorus product.

Timeline

Start

—

Primary completion

—

Completion

—

Publications

• Results Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J; CONTROL Investigators. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol. 2006 Mar;1(2):305-12. doi: 10.2215/CJN.00870805. Epub 2006 Jan 25.

Drugs

Indications